GLG LLC’s Clovis Oncology, Inc. CLVS Stock Holding History

GLG LLC’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-123,300	Closed	-$4.45M	–	551
2016 Q3	$4.45M	Buy	+123,300	New	+$2.65M	0.32%	84

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

GLG LLC's CLVS Position: Q4 2017 in Review

GLG LLC held its Clovis Oncology, Inc. (CLVS) position steady in Q4 2017 at 27,883 shares worth $1.9M. The position accounts for 0.14% of the portfolio, ranked #184.

GLG LLC first reported a position in CLVS in Q3 2016 and has held it in 5 quarters since. The position peaked at $2.3M in Q3 2017. 247 funds tracked by Wall St. Rank hold CLVS as of Q4 2017.

GLG LLC held 27,883 shares of Clovis Oncology, Inc. worth $1.9M as of Q4 2017.
GLG LLC left its Clovis Oncology, Inc. share count unchanged in Q4 2017.
Clovis Oncology, Inc. made up 0.14% of GLG LLC's portfolio in Q4 2017, its #184 holding.
GLG LLC first reported a position in Clovis Oncology, Inc. in Q3 2016 and has held it in 5 quarters since.
GLG LLC's Clovis Oncology, Inc. position peaked at $2.3M in Q3 2017.
247 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2017.

Based on GLG LLC's 13F filing for Q4 2017, filed 14 Feb 2018.